News Release

PROTAC technology for prostate cancer treatment

Peer-Reviewed Publication

Compuscript Ltd

https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0075

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites, such as bones, the pelvis, and various visceral organs. Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression, gene amplification, and the rise of androgen receptor splice variants. Although androgen deprivation therapy remains the mainstay for early-stage PrCa treatment, efficacy is temporary because many cases advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle. This review explores key biomarkers for PrCa and the latest therapeutic strategies for CRPC with a particular focus on the innovative proteolysis-targeting chimera (PROTAC) technology. This approach offers a novel means of degrading target proteins and we discuss how PROTAC holds potential as effective strategies to combat resistance mechanisms in CRPC.

# # # # # #

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed

Queries about the journal can be sent to editorialoffice@amm-journal.org.

Please visit https://amm-journal.org/ to learn more about the journal.

Editorial Board: https://amm-journal.org/index.php/editorial-board/

There are no author submission or article processing fees.

 

Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal; Facebook (https://www.facebook.com/AMMjournal)

eISSN 2737-7946

# # # # # #

Zhen Wang, Dingpeng Zhang and Hiroyuki Inuzuka et al. PROTAC technology for prostate cancer treatment. Acta Materia Medica. 2025. Vol. 4(1):99-121. DOI: 10.15212/AMM-2024-0075


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.